Bassam Kanaan

Bassam Kanaan is a declared insider of Hikma Pharmaceuticals PLC, with filings sourced from RNS (LSE). The record holds 11 filings, for trades running from 9 August 2023 to 1 June 2026.

Market trades split into 4 purchases and 3 sales (€1.4M). The totals exclude 4 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 4 share grants. Since January 2026: 2 purchases and no sales on the market.

Of 4 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 5 June 2026, the filings show an open-market purchase in Hikma Pharmaceuticals PLC. The median gap between a trade and its publication by RNS (LSE) is 2 days. Under the UK Market Abuse Regulation, managers have three business days to notify their trades. This summary is built from RNS (LSE) disclosures alone and does not predict where the share price will go.